These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 29085193

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS, Park MH, Jeon GS.
    Acta Radiol; 2011 Apr 01; 52(3):331-5. PubMed ID: 21498371
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.
    BMC Cancer; 2015 Jun 10; 15():465. PubMed ID: 26059447
    [Abstract] [Full Text] [Related]

  • 66. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, Kudo M.
    Oncology; 2017 Jun 10; 93 Suppl 1():120-126. PubMed ID: 29258105
    [Abstract] [Full Text] [Related]

  • 67. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY.
    Liver Int; 2014 Apr 10; 34(4):612-20. PubMed ID: 24028297
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
    Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB.
    Acta Radiol; 2012 Jun 01; 53(5):545-50. PubMed ID: 22547388
    [Abstract] [Full Text] [Related]

  • 70. [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].
    Herber S, Pitton M, Mönch C, Schneider J, Manzl N, Kummer I, Kanzler S, Schuchmann M, Junginger T, Düber C, Otto G.
    Zentralbl Chir; 2007 Aug 01; 132(4):306-15. PubMed ID: 17724633
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
    Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M.
    Eur J Gastroenterol Hepatol; 2019 Nov 01; 31(11):1414-1423. PubMed ID: 31045613
    [Abstract] [Full Text] [Related]

  • 73. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
    Carling U, Røsok B, Line PD, Dorenberg EJ.
    Acta Radiol; 2019 Jun 01; 60(6):702-709. PubMed ID: 30205701
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH.
    Cardiovasc Intervent Radiol; 2018 Mar 01; 41(3):459-465. PubMed ID: 29067511
    [Abstract] [Full Text] [Related]

  • 77. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, Ingrand P, Tasu JP.
    Eur Radiol; 2016 Jun 01; 26(6):1640-8. PubMed ID: 26455721
    [Abstract] [Full Text] [Related]

  • 78. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
    Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM.
    J Vasc Interv Radiol; 2014 Jan 01; 25(1):32-40. PubMed ID: 24290099
    [Abstract] [Full Text] [Related]

  • 79. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.
    J Vasc Interv Radiol; 2014 Feb 01; 25(2):248-55.e1. PubMed ID: 24295569
    [Abstract] [Full Text] [Related]

  • 80. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb 01; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.